Article Details
Retrieved on: 2024-11-17 23:01:09
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the AZALEA-TIMI 71 trial, highlighting abelacimab's ability to reduce bleeding in atrial fibrillation patients, demonstrating significant healing potential compared to rivaroxaban. It connects key concepts like anticoagulation and stroke management with the tag 'healing'.
Article found on: www.pharmacytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here